Brokerages predict that Albireo Pharma Inc (NASDAQ:ALBO) will post ($1.37) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Albireo Pharma’s earnings. The lowest EPS estimate is ($1.45) and the highest is ($1.28). Albireo Pharma posted earnings of ($0.15) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 813.3%. The company is scheduled to issue its next quarterly earnings report before the market opens on Thursday, May 16th.
According to Zacks, analysts expect that Albireo Pharma will report full-year earnings of ($6.02) per share for the current fiscal year, with EPS estimates ranging from ($7.05) to ($5.16). For the next fiscal year, analysts forecast that the company will post earnings of ($5.49) per share, with EPS estimates ranging from ($7.10) to ($4.47). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Albireo Pharma.
Albireo Pharma (NASDAQ:ALBO) last issued its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.16) by ($0.18). Albireo Pharma had a negative net margin of 361.94% and a negative return on equity of 32.42%. The business had revenue of $0.57 million during the quarter, compared to analyst estimates of $1.94 million.
A number of brokerages recently weighed in on ALBO. ValuEngine raised shares of Albireo Pharma from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 26th. BidaskClub raised shares of Albireo Pharma from a “hold” rating to a “buy” rating in a research report on Wednesday, March 6th. Cowen reaffirmed a “buy” rating on shares of Albireo Pharma in a research report on Wednesday, April 17th. Zacks Investment Research cut shares of Albireo Pharma from a “hold” rating to a “sell” rating in a research report on Monday, March 11th. Finally, Wedbush reaffirmed a “buy” rating and set a $69.00 price target on shares of Albireo Pharma in a research report on Friday, January 25th. One analyst has rated the stock with a sell rating, four have issued a buy rating and two have assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $54.25.
Shares of Albireo Pharma stock opened at $36.20 on Friday. Albireo Pharma has a twelve month low of $19.10 and a twelve month high of $37.95. The firm has a market cap of $437.75 million, a P/E ratio of -9.19 and a beta of 1.72.
Several institutional investors have recently modified their holdings of the company. BlackRock Inc. raised its stake in shares of Albireo Pharma by 11.4% in the 3rd quarter. BlackRock Inc. now owns 584,177 shares of the biopharmaceutical company’s stock valued at $19,255,000 after purchasing an additional 59,901 shares in the last quarter. Prosight Management LP raised its stake in shares of Albireo Pharma by 65.8% in the 4th quarter. Prosight Management LP now owns 270,146 shares of the biopharmaceutical company’s stock valued at $6,627,000 after purchasing an additional 107,241 shares in the last quarter. Sectoral Asset Management Inc raised its stake in shares of Albireo Pharma by 21.3% in the 4th quarter. Sectoral Asset Management Inc now owns 229,978 shares of the biopharmaceutical company’s stock valued at $5,641,000 after purchasing an additional 40,400 shares in the last quarter. Fosun International Ltd acquired a new stake in shares of Albireo Pharma in the 4th quarter valued at about $4,492,000. Finally, Chicago Capital LLC raised its stake in shares of Albireo Pharma by 4.7% in the 1st quarter. Chicago Capital LLC now owns 189,408 shares of the biopharmaceutical company’s stock valued at $6,101,000 after purchasing an additional 8,497 shares in the last quarter. Institutional investors and hedge funds own 66.91% of the company’s stock.
Albireo Pharma Company Profile
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Recommended Story: How Important is Technical Analysis of Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.